<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Beilstein J Org Chem</journal-id><journal-id journal-id-type="iso-abbrev">Beilstein J Org Chem</journal-id><journal-title-group><journal-title>Beilstein Journal of Organic Chemistry</journal-title></journal-title-group><issn pub-type="epub">1860-5397</issn><publisher><publisher-name>Beilstein-Institut</publisher-name><publisher-loc>Trakehner Str. 7-9, 60487 Frankfurt am Main, Germany</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27829885</article-id><article-id pub-id-type="pmc">5082444</article-id><article-id pub-id-type="doi">10.3762/bjoc.12.168</article-id><article-categories><subj-group subj-group-type="heading"><subject>Full Research Paper</subject></subj-group><subj-group subj-group-type="topic"><subject>Chemistry</subject><subj-group subj-group-type="topic"><subject>Organic Chemistry</subject></subj-group></subj-group></article-categories><title-group><article-title>Synthesis of pyrrolo[2,1-<italic>f</italic>][1,2,4]triazin-4(3<italic>H</italic>)-ones: Rearrangement of pyrrolo[1,2-<italic>d</italic>][1,3,4]oxadiazines and regioselective intramolecular cyclization of 1,2-biscarbamoyl-substituted 1<italic>H</italic>-pyrroles</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Son</surname><given-names>Kkonnip</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Park</surname><given-names>Seong Jun</given-names></name><email>sjunpark@krict.re.kr</email><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Baxendale</surname><given-names>Ian R</given-names></name><role>Associate Editor</role></contrib></contrib-group><aff id="A1"><label>1</label>Research Center for Medicinal Chemistry, Korea Research Institute of Chemical Technology (KRICT), 141 Gajeong-ro, Yuseong-gu, Daejeon 305-600, Korea</aff><aff id="A2"><label>2</label>Department of Chemistry, Sogang University, 35 Baekbeom-ro, Mapo-gu, Seoul 121-742, Korea</aff><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>9</day><month>8</month><year>2016</year></pub-date><volume>12</volume><fpage>1780</fpage><lpage>1787</lpage><ext-link ext-link-type="doi" xlink:href="10.3762/bjoc.12.168">10.3762/bjoc.12.168</ext-link><history><date date-type="received"><day>10</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>19</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016, Son and Park</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Son and Park</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license license-type="Beilstein"><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/2.0</ali:license_ref><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://www.beilstein-journals.org/bjoc/terms</ali:license_ref><license-p>This is an Open Access article under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/2.0">https://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p><license-p>The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (<ext-link ext-link-type="uri" xlink:href="https://www.beilstein-journals.org/bjoc/terms">https://www.beilstein-journals.org/bjoc/terms</ext-link>)</license-p></license></permissions><abstract><p>Pyrrolo[2,1-<italic>f</italic>][1,2,4]triazin-4(3<italic>H</italic>)-ones <bold>12</bold> have been easily prepared via nucleophile-induced rearrangement of pyrrolooxadiazines <bold>11</bold> and regioselective intramolecular cyclization of 1,2-biscarbamoyl-substituted 1<italic>H</italic>-pyrroles <bold>10</bold>. In this work, we demonstrated that the described synthetic approaches can be considered to be more facile and practical than previously reported procedures.</p></abstract><kwd-group kwd-group-type="author"><kwd>intramolecular cyclization</kwd><kwd>pyrrolooxadiazines</kwd><kwd>pyrrolotriazinone</kwd><kwd>rearrangement</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Pyrrolo[2,1-<italic>f</italic>][1,2,4]triazin-4(3<italic>H</italic>)-ones have been considered to be biologically active compounds. For example, these nitrogen-containing heterocycles have shown intriguing activities as tankyrase inhibitors <bold>1</bold> [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R2" ref-type="bibr">2</xref>], stearoyl CoA desaturase inhibitors <bold>2</bold> [<xref rid="R3" ref-type="bibr">3</xref>], Eg5 inhibitors <bold>3</bold> [<xref rid="R4" ref-type="bibr">4</xref>&#x02013;<xref rid="R5" ref-type="bibr">5</xref>], melanin-concentrating hormone receptor (MCH)-R1 antagonists <bold>4</bold> [<xref rid="R6" ref-type="bibr">6</xref>], and CRF1 receptor antagonists <bold>5</bold> [<xref rid="R7" ref-type="bibr">7</xref>&#x02013;<xref rid="R8" ref-type="bibr">8</xref>] (<xref ref-type="fig" rid="F1">Figure 1</xref>). Notably, many patent applications have described pyrrolotriazinones as phosphoinositide 3-kinase (PI3K) inhibitors <bold>6</bold> [<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R12" ref-type="bibr">12</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Bioactive pyrrolo[2,1-<italic>f</italic>][1,2,4]triazin-4(3<italic>H</italic>)-ones [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R12" ref-type="bibr">12</xref>].</p></caption><graphic xlink:href="Beilstein_J_Org_Chem-12-1780-g002"/></fig><p>These skeletons are the key intermediates for the synthesis of pyrrolo[2,1-<italic>f</italic>][1,2,4]triazines, which have been shown to have outstanding biological activities [<xref rid="R13" ref-type="bibr">13</xref>&#x02013;<xref rid="R17" ref-type="bibr">17</xref>]. Consequently, many research groups have developed synthetic approaches; two main synthetic routes involve <italic>N</italic>-imine intermediates and could be considered for the preparation of pyrrolotriazinones (<xref ref-type="fig" rid="F2">Figure 2</xref>). Based on the reported cyclization methods, however, the reactions require high temperatures and long reaction times (generally overnight) to obtain the desired products [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R12" ref-type="bibr">12</xref>]. For example, these cyclization methods involve procedures such as microwave-assisted heating with NaOMe [<xref rid="R1" ref-type="bibr">1</xref>] and H<sub>2</sub>N-Ar [<xref rid="R6" ref-type="bibr">6</xref>] at 150&#x02013;160 &#x000b0;C, refluxing with HC(OEt)<sub>3</sub> [<xref rid="R3" ref-type="bibr">3</xref>] and xylene [<xref rid="R4" ref-type="bibr">4</xref>&#x02013;<xref rid="R5" ref-type="bibr">5</xref><xref rid="R8" ref-type="bibr">8</xref>], stirring at 100 &#x000b0;C in the presence of either NaOH or KOH [<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R9" ref-type="bibr">9</xref>], and heating with POCl<sub>3</sub> [<xref rid="R11" ref-type="bibr">11</xref>] (<xref ref-type="fig" rid="F2">Figure 2</xref>). It is reasonable to consider that these harsh conditions are required because it is difficult to form the <italic>N</italic>-imine structure and to subsequently perform intramolecular cyclization (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>General synthetic routes to pyrrolotriazinones [<xref rid="R3" ref-type="bibr">3</xref>&#x02013;<xref rid="R6" ref-type="bibr">6</xref><xref rid="R8" ref-type="bibr">8</xref>&#x02013;<xref rid="R9" ref-type="bibr">9</xref><xref rid="R11" ref-type="bibr">11</xref>].</p></caption><graphic xlink:href="Beilstein_J_Org_Chem-12-1780-g003"/></fig><p>In our efforts to discover drugs that are PI3K inhibitors, a Hutchison Medipharma patent caught our attention. They reported that pyrrolotriazinones showed excellent inhibitory activities against PI3K enzymes [<xref rid="R9" ref-type="bibr">9</xref>]. However, their synthetic method to prepare the target molecule <bold>9</bold> demonstrated a limited scope, and involved high temperature, long reaction time, and low yield (approach A, <xref ref-type="fig" rid="C1">Scheme 1</xref>). Another synthetic approach, reported by researchers at Infinity Pharmaceuticals Inc., has been used to obtain triazinone <bold>12a&#x02019;</bold> via rearrangement of oxadiazines <bold>11a&#x02019;</bold> (approach B, <xref ref-type="fig" rid="C1">Scheme 1</xref>) [<xref rid="R10" ref-type="bibr">10</xref>].</p><fig id="C1" position="float"><label>Scheme 1</label><caption><p>Synthesis of pyrrolotriazinones <bold>9</bold> and <bold>12</bold> [<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R10" ref-type="bibr">10</xref><xref rid="R18" ref-type="bibr">18</xref>].</p></caption><graphic xlink:href="Beilstein_J_Org_Chem-12-1780-g006"/></fig><p>However, in our investigation of the reported rearrangement reaction, the desired product <bold>12a&#x02019;</bold> was not accessed (approach B, <xref ref-type="fig" rid="C1">Scheme 1</xref>). For the procedure using silica-gel column chromatography to afford triazinone <bold>12a&#x02019;</bold> from the free amine-containing oxadiazine <bold>11a&#x02019;</bold> [<xref rid="R10" ref-type="bibr">10</xref>], compound <bold>11a&#x02019;</bold> was not present after the boc-deprotection reaction because of its instability in the acidic conditions.</p><p>Based on the literature and the attempts reported herein, it should be highlighted that limitations exist for the preparation of the desired compounds <bold>12</bold>. Due to these difficulties, we have investigated the synthesis of pyrrolotriazinones <bold>12</bold> by using a more convenient and facile approach than those that have been previously reported in the literature [<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R12" ref-type="bibr">12</xref>].</p></sec><sec><title>Results and Discussion</title><p>Our studies started with the synthesis of aminopyrrolocarbamate <bold>10</bold>. The preparation of compound <bold>10</bold>, which is illustrated in <xref ref-type="fig" rid="C2">Scheme 2</xref>, involved chlorination of 3-chloro-1<italic>H</italic>-pyrrole-2-carboxylic acid (<bold>13</bold>) using the Vilsmeier reagent [<xref rid="R9" ref-type="bibr">9</xref>], followed by further amination to produce 1<italic>H</italic>-pyrrole-2-carboxamide <bold>14</bold> in good to excellent yield [<xref rid="R9" ref-type="bibr">9</xref>]. A reaction mixture of <bold>14</bold> with NaOH, NH<sub>4</sub>Cl, and NaClO led to the formation of the <italic>N</italic>-aminopyrrole <bold>15</bold> [<xref rid="R11" ref-type="bibr">11</xref>]. The addition of the NH<sub>2</sub><sup>+</sup> to the nitrogen of pyrrole <bold>14</bold> by using the NaOH/NH<sub>4</sub>Cl/NaClO system [<xref rid="R11" ref-type="bibr">11</xref>] can be considered as a more practical method than others, such as those that use NH<sub>2</sub>Cl and HOSA [<xref rid="R19" ref-type="bibr">19</xref>]. In contrast to other substituents, 2-fluorophenyl and 4-cyanophenyl groups caused low yields (<bold>15b</bold>: 15%, <bold>15f</bold>: 31%). The <italic>N</italic>-aminopyrroles <bold>15</bold> were then reacted with EDC&#x000b7;HCl and Boc-L-alanine in THF to give the desired aminopyrrolocarbamate <bold>10</bold> in good to excellent yield [<xref rid="R9" ref-type="bibr">9</xref>].</p><fig id="C2" position="float"><label>Scheme 2</label><caption><p>Synthesis of aminopyrrolocarbamate <bold>10</bold>.</p></caption><graphic xlink:href="Beilstein_J_Org_Chem-12-1780-g007"/></fig><p>To synthesize the desired pyrrolotriazinones <bold>12</bold> regioselectively we initially considered the work of Mazurkiewicz [<xref rid="R20" ref-type="bibr">20</xref>&#x02013;<xref rid="R21" ref-type="bibr">21</xref>]. He reported that a mixture of 4<italic>H</italic>-3,1-benzoxazines (<italic>O</italic>-imidoylation products) and 4-quinazolones (<italic>N</italic>-imidoylation products) could be obtained after heating <italic>N</italic>-acylanthranilamides in CH<sub>2</sub>Cl<sub>2</sub> under reflux with PPh<sub>3</sub>Br<sub>2</sub> in the absence of triethylamine. In his research, it was proved that HCl or HBr influenced the rearrangement of benzoxazines to quinazolones. Importantly, triethylamine was considered to be an HBr captor [<xref rid="R20" ref-type="bibr">20</xref>&#x02013;<xref rid="R21" ref-type="bibr">21</xref>].</p><p>With regard to Mazurkiewicz&#x02019;s work, the effect of Et<sub>3</sub>N on intramolecular cyclization was explored, and the acid-assisted rearrangement was also evaluated.</p><p>As shown in <xref rid="T1" ref-type="table">Table 1</xref>, although all of the obtained yields were influenced by the amount of Et<sub>3</sub>N, the attempt to synthesize compound <bold>12a</bold> directly by optimizing the amount of base was not successful. For example, no reaction was observed in the absence Et<sub>3</sub>N (entry 1, <xref rid="T1" ref-type="table">Table 1</xref>). When excess amounts of base were used, compounds <bold>11a</bold> and <bold>12a</bold> were only obtained in low yields (40% combined yield, entry 3, <xref rid="T1" ref-type="table">Table 1</xref>). Alternatively, when 2.5 equivalents of Et<sub>3</sub>N were used, the two regioisomers <bold>11a</bold> and <bold>12a</bold> were obtained in an excellent overall yield of 87% (entry 2, <xref rid="T1" ref-type="table">Table 1</xref>). In addition, the ratio of <bold>11a</bold> to <bold>12a</bold> was not significantly affected by reaction times and temperatures (entries 4&#x02013;6, <xref rid="T1" ref-type="table">Table 1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>The studies on various reaction conditions.</p></caption><table frame="hsides" rules="groups"><tr><td align="center" colspan="4" valign="middle" rowspan="1"><inline-graphic xlink:href="Beilstein_J_Org_Chem-12-1780-i001.jpg"/></td></tr><tr><td align="center" colspan="4" valign="middle" rowspan="1"><hr/></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Entry</td><td align="center" valign="middle" rowspan="1" colspan="1">Et<sub>3</sub>N (equiv)</td><td align="center" valign="middle" rowspan="1" colspan="1">Reaction conditions</td><td align="center" valign="middle" rowspan="1" colspan="1">Yield [%]<sup>a </sup><bold>11a</bold> (<bold>12a</bold>)</td></tr><tr><td align="left" colspan="4" valign="middle" rowspan="1"><hr/></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">None</td><td align="center" valign="middle" rowspan="1" colspan="1">0 &#x000b0;C, 1 h &#x02192; rt, 0.5 h</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;<sup>b</sup> (&#x02013;<sup>b</sup>)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0 &#x000b0;C, 5 min</td><td align="center" valign="middle" rowspan="1" colspan="1">53 (34)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">0 &#x000b0;C, 5 min</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (29)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0 &#x000b0;C, 5 min</td><td align="center" valign="middle" rowspan="1" colspan="1">68 (22)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0 &#x000b0;C, 1 h &#x02192; rt, 6 h</td><td align="center" valign="middle" rowspan="1" colspan="1">63 (20)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">reflux, 10 min</td><td align="center" valign="middle" rowspan="1" colspan="1">59 (16)</td></tr></table><table-wrap-foot><fn id="TFN1"><p><sup>a</sup>After column chromatography, <sup>b</sup>not obtained.</p></fn></table-wrap-foot></table-wrap><p>Although initial attempts to synthesize pyrrolotriazinone <bold>12a</bold> regioselectively were not successful, it should be highlighted that the regioisomers oxadiazine <bold>11a</bold> and triazinone <bold>12a</bold> could be easily prepared under very mild conditions (0 &#x000b0;C for 5 min), whereas only the oxadiazine <bold>11a</bold> had been obtained in other reported procedures [<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R12" ref-type="bibr">12</xref>].</p><p>The acid-promoted rearrangement of oxadiazine <bold>11</bold> to triazinone <bold>12</bold> was also examined. However, the trial reaction was not successful because compound <bold>11</bold> did not tolerate acidic conditions.</p><p>Because of this result, the rearrangement reaction of pyrrolooxadiazine <bold>11a</bold> to pyrrolotriazinone <bold>12a</bold> was explored (<xref rid="T2" ref-type="table">Table 2</xref>). For nucleophile-induced cyclization, pyrrolidine, Li(Me<sub>3</sub>AlSPh) [<xref rid="R22" ref-type="bibr">22</xref>], NaSMe, and NaOMe were assessed. Attempting the Mazurciewitcz&#x02013;Ganesan procedure [<xref rid="R23" ref-type="bibr">23</xref>], using pyrrolidine as a nucleophile, was not successful (entry 1, <xref rid="T2" ref-type="table">Table 2</xref>). In the cases of Li[Me<sub>3</sub>AlSPh], NaSMe, and NaOMe, the triazinone <bold>12a</bold> was readily obtained after the nucleophilic-addition/ring-closure reaction (entries 2&#x02013;5, <xref rid="T2" ref-type="table">Table 2</xref>). For example, similar to benzoxazine [<xref rid="R22" ref-type="bibr">22</xref>], treatment of <bold>11a</bold> and <bold>11d</bold> with lithium trimethyl(phenylsulfido)aluminate Li(Me<sub>3</sub>AlSPh) provided the desired pyrrolotriazinone, <bold>12a</bold> and <bold>12d</bold>, in excellent yields and with retention of enantiomeric excesses (ee) (entries 2 and 3, <xref rid="T2" ref-type="table">Table 2</xref>). Interestingly, the rearrangement of oxadiazine <bold>11a</bold> with sodium thiomethoxide led to the desired compound <bold>12a</bold> (92% yield, entry 4, <xref rid="T2" ref-type="table">Table 2</xref>), and retention of ee was observed. With sodium methoxide, the ee was not retained, but the desired product <bold>12a</bold> was obtained in excellent yield (entry 5, <xref rid="T2" ref-type="table">Table 2</xref>). Notably, it has proven that sulfur-based reagents such as Li(Me<sub>3</sub>AlSPh) and NaSMe are efficient for the nucleophile-induced cyclization.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Rearrangement of pyrrolooxadiazine <bold>11</bold> to pyrrolotriazinone <bold>12</bold>.</p></caption><table frame="hsides" rules="groups"><tr><td align="center" colspan="6" valign="middle" rowspan="1"><inline-graphic xlink:href="Beilstein_J_Org_Chem-12-1780-i002.jpg"/></td></tr><tr><td align="center" colspan="6" valign="middle" rowspan="1"><hr/></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Entry</td><td align="center" valign="middle" rowspan="1" colspan="1">R</td><td align="center" valign="middle" rowspan="1" colspan="1">Substrate/Product</td><td align="center" valign="middle" rowspan="1" colspan="1">Rearrangement conditions</td><td align="center" valign="middle" rowspan="1" colspan="1">Yield [%]<sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">ee [%]<sup>b</sup></td></tr><tr><td align="left" colspan="6" valign="middle" rowspan="1"><hr/></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Ph</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11a</bold>/<bold>12a</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1. pyrrolidine, rt, 18 h<break/>2. AcOH, CH<sub>3</sub>CN</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;<sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;<sup>d</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Ph</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11a</bold>/<bold>12a</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">Li(Me<sub>3</sub>AlSPh), THF, rt, 20 h</td><td align="center" valign="middle" rowspan="1" colspan="1">90</td><td align="center" valign="middle" rowspan="1" colspan="1">99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">4-F-Ph</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11d</bold>/<bold>12d</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">Li(Me<sub>3</sub>AlSPh), THF, rt, 20 h</td><td align="center" valign="middle" rowspan="1" colspan="1">69</td><td align="center" valign="middle" rowspan="1" colspan="1">99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Ph</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11a</bold>/<bold>12a</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">NaSMe, THF/DMF, rt, 0.5 h</td><td align="center" valign="middle" rowspan="1" colspan="1">92</td><td align="center" valign="middle" rowspan="1" colspan="1">99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">Ph</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11a</bold>/<bold>12a</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">NaOMe, THF/DMF, rt, 3 h</td><td align="center" valign="middle" rowspan="1" colspan="1">85</td><td align="center" valign="middle" rowspan="1" colspan="1">88</td></tr></table><table-wrap-foot><fn id="TFN2"><p><sup>a</sup>After column chromatography; <sup>b</sup>the enantiomeric excess (ee) was determined after the amide coupling reaction of boc-deprotected <bold>12</bold> with moscher&#x02019;s acid; <sup>c</sup>not obtained; <sup>d</sup>not determined.</p></fn></table-wrap-foot></table-wrap><p>Next, the effect of different halogens on the regioselectivity of the cyclization of <bold>10</bold> was investigated (<xref rid="T3" ref-type="table">Table 3</xref>). In general, the mixture of oxadiazines <bold>11</bold> and triazinones <bold>12</bold> was obtained in 45&#x02013;98% overall yield. The results show that the regioselectivity is highly dependent on the halogen used. In particular, when PPh<sub>3</sub>Cl<sub>2</sub> was used, triazinones <bold>12</bold> (<italic>N</italic>-imidoylation product) were more easily obtained than oxadiazines <bold>11</bold> (entries 1 and 4&#x02013;6, <xref rid="T3" ref-type="table">Table 3</xref>). In the case of bromine, the <italic>O</italic>-imidoylation products <bold>11</bold> were preferred over the <italic>N</italic>-imidoylation products <bold>12</bold>, whereas for substrates with 2- and 3-fluorophenyl groups different results were obtained (entries 2 and 8&#x02013;11, <xref rid="T3" ref-type="table">Table 3</xref>). Based on the literature results [<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R12" ref-type="bibr">12</xref><xref rid="R22" ref-type="bibr">22</xref>&#x02013;<xref rid="R25" ref-type="bibr">25</xref>] and the reactions that are reported herein, the <italic>O</italic>-imidoylation product <bold>11</bold> is more accessible than the <italic>N</italic>-imidoylation product <bold>12</bold> when PPh<sub>3</sub>-Br<sub>2</sub>/I<sub>2</sub>-Et<sub>3</sub>N/DIPEA systems are applied (entries 2, 3, 10 and 11, <xref rid="T3" ref-type="table">Table 3</xref>).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Investigation of regioselectivity.</p></caption><table frame="hsides" rules="groups"><tr><td align="center" colspan="5" valign="middle" rowspan="1"><inline-graphic xlink:href="Beilstein_J_Org_Chem-12-1780-i003.jpg"/></td></tr><tr><td align="center" colspan="5" valign="middle" rowspan="1"><hr/></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Entry</td><td align="center" valign="middle" rowspan="1" colspan="1">R</td><td align="center" valign="middle" rowspan="1" colspan="1">X<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Products</td><td align="center" valign="middle" rowspan="1" colspan="1">Yield [%]<sup>a </sup><bold>11</bold> (<bold>12</bold>)</td></tr><tr><td align="left" colspan="5" valign="middle" rowspan="1"><hr/></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">phenyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Cl</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11a</bold> (<bold>12a</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (87)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">phenyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Br</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11a</bold> (<bold>12a</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">63 (18)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">phenyl</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11a</bold> (<bold>12a</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">81 (13)</td></tr><tr><td align="left" colspan="5" valign="middle" rowspan="1"><hr/></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">3-fluorophenyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Cl</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11c</bold> (<bold>12c</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (72)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">4-fluorophenyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Cl</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11d</bold> (<bold>12d</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (81)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">4-methoxyphenyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Cl</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11e</bold> (<bold>12e</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (78)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">4-cyanophenyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Cl</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11f</bold> (<bold>12f</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (41)</td></tr><tr><td align="left" colspan="5" valign="middle" rowspan="1"><hr/></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">2-fluorophenyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Br</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11b</bold> (<bold>12b</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (29)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">3-fluorophenyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Br</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11c</bold> (<bold>12c</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (68)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">4-fluorophenyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Br</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11d</bold> (<bold>12d</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (19)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">4-methoxyphenyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Br</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11e</bold> (<bold>12e</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">70 (10)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">4-cyanophenyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Br</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11f</bold> (<bold>12f</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;<sup>b</sup> (&#x02013;<sup>b</sup>)</td></tr><tr><td align="left" colspan="5" valign="middle" rowspan="1"><hr/></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">4-methoxybenzyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Br</td><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>12g</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;<sup>b</sup> (60)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">cyclopropyl</td><td align="center" valign="middle" rowspan="1" colspan="1">Br</td><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>12h</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;<sup>b</sup> (66)</td></tr></table><table-wrap-foot><fn id="TFN3"><p><sup>a</sup>After column chromatography; <sup>b</sup>not obtained.</p></fn></table-wrap-foot></table-wrap><p>Interestingly, in the case of the 4-cyanophenyl group, it appeared that the different reaction patterns might be a result of the reagents PPh<sub>3</sub>Br<sub>2</sub> and PPh<sub>3</sub>Cl<sub>2</sub> (entries 7 and 12, <xref rid="T3" ref-type="table">Table 3</xref>). For alkyl substituents (4-methoxybenzyl and cyclopropyl, entries 13 and 14, <xref rid="T3" ref-type="table">Table 3</xref>), triazinones <bold>12g</bold> and <bold>12h</bold> were selectively prepared in over 60% yield. Based on these results, it is possible to consider that due to the presence of electron-donating groups, such as alkyl substituents, only the <italic>N</italic>-imidoylation products <bold>12g</bold>, and <bold>12h</bold> were formed.</p><p>It is possible to propose a reaction mechanism after considering our studies and the literature results (<xref ref-type="fig" rid="F3">Figure 3</xref>) [<xref rid="R20" ref-type="bibr">20</xref>&#x02013;<xref rid="R28" ref-type="bibr">28</xref>]. For example, it is not reasonable to consider Mazurkiewicz&#x02019;s acid-promoted rearrangement [<xref rid="R20" ref-type="bibr">20</xref>&#x02013;<xref rid="R21" ref-type="bibr">21</xref>], because oxadiazine is not stable under acidic conditions. In the case of the rearrangement of <bold>11a</bold> to <bold>12a</bold>, the mechanism of the nucleophile-induced cyclization is proposed after considering Hart&#x02019;s research on the synthesis of fumiquinazolines [<xref rid="R22" ref-type="bibr">22</xref>]. It was shown that the nucleophilicity of the <italic>N</italic>-acylnitrenium ion was increased when the oxygen ion was stabilized by counter ions such as lithium and sodium. For the intramolecular cyclization step, it was shown that the regioselectivity depends on the halogen source (Br/Cl) and neighboring groups of the <italic>N</italic>-acylnitrenium ions (electron-withdrawing aryl and -donating alkyl substitutents). This is highlighted by the observation that the <italic>N</italic>-imidoylation product (triazinone) <bold>12</bold> was preferentially obtained when a chlorine-halogen source and electron-donating alkyl groups were used. While further studies are required, we suggest the intermediates are <italic>N</italic>-acylnitrenium ions [<xref rid="R26" ref-type="bibr">26</xref>] and halogen-imine structures (the Vilsmeier type) [<xref rid="R27" ref-type="bibr">27</xref>&#x02013;<xref rid="R28" ref-type="bibr">28</xref>].</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Probable mechanism for the synthesis of triazinone <bold>12a</bold>.</p></caption><graphic xlink:href="Beilstein_J_Org_Chem-12-1780-g004"/></fig><p>Because oxadiazines <bold>11</bold> and triazinones <bold>12</bold> are non-crystalline, their exact structures were assigned by NMR spectroscopy (<sup>1</sup>H and <sup>13</sup>C). With the literature results alone [<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R12" ref-type="bibr">12</xref>] the identity of the regioisomers could not be accurately confirmed; therefore, the NMR studies were required. As shown in <xref rid="T4" ref-type="table">Table 4</xref>, different NOEs were observed for compounds <bold>11</bold> and <bold>12</bold>.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>NOE analysis of representative examples (<bold>11a</bold>/<bold>11d</bold> and <bold>12a</bold>/<bold>12d</bold>).</p></caption><table frame="hsides" rules="groups"><tr><td align="center" colspan="5" valign="middle" rowspan="1"><inline-graphic xlink:href="Beilstein_J_Org_Chem-12-1780-i004.jpg"/></td></tr><tr><td align="center" colspan="5" valign="middle" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="2" valign="middle" colspan="1">Entry</td><td align="center" rowspan="2" valign="middle" colspan="1">R<sup>1</sup></td><td align="center" rowspan="2" valign="middle" colspan="1">Product</td><td align="center" colspan="2" valign="middle" rowspan="1">NOEs</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">H<sup>a</sup>&#x02013;H<sup>b</sup> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">H<sup>a</sup>&#x02013;H<sup>c</sup> (%)</td></tr><tr><td align="left" colspan="5" valign="middle" rowspan="1"><hr/></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11a</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>11d</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>12a</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>12d</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">42</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td></tr></table></table-wrap><p>Upon examination of the <sup>1</sup>H NMR spectra of oxadiazines <bold>11</bold> and triazinones <bold>12</bold>, different peak patterns of the NH protons were observed (<bold>11</bold> &#x02013; NH: 4.8 ppm, <bold>12</bold> &#x02013; NH: 5.1 ppm, see <xref ref-type="supplementary-material" rid="SD1">Supporting Information File 1</xref>).</p><p>Through <sup>13</sup>C NMR and IR analysis the presence of two regioisomers could be confirmed by the peaks of specific functional groups (<xref ref-type="fig" rid="F4">Figure 4</xref>).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>The results of <sup>13</sup>C NMR and IR studies.</p></caption><graphic xlink:href="Beilstein_J_Org_Chem-12-1780-g005"/></fig><p>According to the NMR and IR data, compounds <bold>11</bold> and <bold>12</bold> are believed to have pyrrolooxadiazine and pyrrolotriazinone structures, respectively. Notably, this is the first report in which the exact structures of these regioisomers have been determined.</p></sec><sec><title>Conclusion</title><p>In summary, to develop straightforward methods for the synthesis of pyrrolo[2,1-<italic>f</italic>][1,2,4]triazin-4(3<italic>H</italic>)-ones, intramolecular cyclization and rearrangement reactions were investigated. Notably, we found that triazinones <bold>12</bold> can be readily accessed under very mild conditions (0 &#x000b0;C, 5 min). The regioselectivity was influenced by the identities of halogen sources of triphenylphosphorane and the <italic>N</italic>-functional groups. For the rearrangement reaction, it was demonstrated that triazinone <bold>12a</bold> was easily obtained when counter ions of oxygen such as lithium and sodium were used. Finally, we predict that these methods could be useful for the preparation of biologically active pyrrolotriazinones and -triazines.</p></sec><sec sec-type="supplementary-material"><title>Supporting Information</title><supplementary-material content-type="local-data" id="SD1"><label>File 1</label><caption><p>Experimental and analytical data.</p></caption><media mime-subtype="pdf" mimetype="application" xlink:href="Beilstein_J_Org_Chem-12-1780-s001.pdf" xlink:type="simple" id="d39e1677" position="anchor"/></supplementary-material></sec></body><back><ref-list><ref id="R1"><label>1</label><element-citation publication-type="patent"><person-group person-group-type="inventor"><name><surname>Dorsch</surname><given-names>D</given-names></name><name><surname>Buschstaller</surname><given-names>H-P</given-names></name></person-group><article-title>Pyrrolotriazinone derivatives</article-title><source>WO Patent</source><patent>WO2013164061 A1</patent><year>2013</year><month>11</month><day>7</day></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannes</surname><given-names>J W</given-names></name><name><surname>Almeida</surname><given-names>L</given-names></name><name><surname>Barlaam</surname><given-names>B</given-names></name><name><surname>Boriack-Sjodin</surname><given-names>P A</given-names></name><name><surname>Casella</surname><given-names>R</given-names></name><name><surname>Croft</surname><given-names>R A</given-names></name><name><surname>Dishington</surname><given-names>A P</given-names></name><name><surname>Gingipalli</surname><given-names>L</given-names></name><name><surname>Gu</surname><given-names>C</given-names></name><name><surname>Hawkins</surname><given-names>J L</given-names></name><etal/></person-group><source>ACS Med Chem Lett</source><year>2015</year><volume>6</volume><fpage>254</fpage><pub-id pub-id-type="doi">10.1021/ml5003663</pub-id><pub-id pub-id-type="pmid">25815142</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="patent"><person-group person-group-type="inventor"><name><surname>Koltun</surname><given-names>D</given-names></name><name><surname>Zablocki</surname><given-names>J</given-names></name><name><surname>Parkhill</surname><given-names>E</given-names></name></person-group><article-title>Pyrrolotriazinone derivatives for use as stearoyl CoA desaturase inhibitors</article-title><source>WO Patent</source><patent>WO2009124259 A1</patent><year>2009</year><month>10</month><day>8</day></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="patent"><person-group person-group-type="inventor"><name><surname>Lombardo</surname><given-names>L J</given-names></name><name><surname>Bhide</surname><given-names>R S</given-names></name><name><surname>Kim</surname><given-names>K S</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name></person-group><article-title>Pyrrolotriazinone compounds and their use to treat diseases</article-title><source>WO Patent</source><patent>WO2003099286 A1</patent><year>2003</year><month>12</month><day>4</day></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K S</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Cornelius</surname><given-names>L A</given-names></name><name><surname>Lombardo</surname><given-names>L J</given-names></name><name><surname>Borzilleri</surname><given-names>R M</given-names></name><name><surname>Schroeder</surname><given-names>G M</given-names></name><name><surname>Sheng</surname><given-names>C</given-names></name><name><surname>Rovnyak</surname><given-names>G</given-names></name><name><surname>Crews</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>R J</given-names></name><etal/></person-group><source>Bioorg Med Chem Lett</source><year>2006</year><volume>16</volume><fpage>3937</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2006.05.037</pub-id><pub-id pub-id-type="pmid">16730979</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="patent"><person-group person-group-type="inventor"><name><surname>Devasthale</surname><given-names>P</given-names></name><name><surname>Washburn</surname><given-names>W N</given-names></name><name><surname>Renduchintala</surname><given-names>K V</given-names></name><name><surname>Sridhar</surname><given-names>R</given-names></name></person-group><article-title>Azolotriazinone melanin concentrating hormone receptor-1 antagonists</article-title><source>WO Patent</source><patent>WO2010042682 A1</patent><year>2010</year><month>4</month><day>15</day><comment>Bristol-Myers Squibb Company.</comment></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="patent"><person-group person-group-type="inventor"><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Obitsu</surname><given-names>T</given-names></name><name><surname>Kagamiishi</surname><given-names>Y</given-names></name></person-group><article-title>Bicyclic heterocyclic compound</article-title><patent>WO 2008136377 A1</patent><year>2008</year><month>11</month><day>13</day></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Obitsu</surname><given-names>T</given-names></name><name><surname>Kohno</surname><given-names>H</given-names></name><name><surname>Sugimoto</surname><given-names>I</given-names></name><name><surname>Matsushita</surname><given-names>T</given-names></name><name><surname>Nishiyama</surname><given-names>T</given-names></name><name><surname>Hirota</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>H</given-names></name><name><surname>Matsumura</surname><given-names>N</given-names></name><name><surname>Ueno</surname><given-names>S</given-names></name><etal/></person-group><source>Bioorg Med Chem</source><year>2012</year><volume>20</volume><fpage>1122</fpage><pub-id pub-id-type="doi">10.1016/j.bmc.2011.11.015</pub-id><pub-id pub-id-type="pmid">22196514</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="patent"><person-group person-group-type="inventor"><name><surname>Su</surname><given-names>W-G</given-names></name><name><surname>Dai</surname><given-names>G</given-names></name><name><surname>Xiao</surname><given-names>K</given-names></name><name><surname>Jia</surname><given-names>H</given-names></name><name><surname>Venable</surname><given-names>J D</given-names></name><name><surname>Bembenek</surname><given-names>S D</given-names></name></person-group><article-title>Novel heteroaryl and heterocycle compounds, compositions and methods</article-title><source>WO Patent</source><patent>WO2014015675 A1</patent><year>2014</year><month>1</month><day>30</day></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="patent"><person-group person-group-type="inventor"><name><surname>Castro</surname><given-names>A C</given-names></name><name><surname>Chan</surname><given-names>K</given-names></name><name><surname>Evans</surname><given-names>C A</given-names></name><name><surname>Janardanannair</surname><given-names>S</given-names></name><name><surname>Lescarbeau</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>P</given-names></name><name><surname>Snyder</surname><given-names>D A</given-names></name><etal/></person-group><article-title>Heterocyclic compounds and uses thereof</article-title><source>U.S. Patent</source><patent>US 20130267521 A1</patent><year>2013</year><month>10</month><day>10</day></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="patent"><person-group person-group-type="inventor"><name><surname>Bernal Anchuela</surname><given-names>F J</given-names></name><name><surname>Carrascal Riere</surname><given-names>M</given-names></name><name><surname>Caturla Javaloyes</surname><given-names>J F</given-names></name><name><surname>Gracia Ferrer</surname><given-names>J</given-names></name><name><surname>Matassa</surname><given-names>V G</given-names></name><name><surname>Terricabras Belart</surname><given-names>E</given-names></name></person-group><article-title>Pyrrolotiazinone derivatives as PI3K inhibitors</article-title><source>European Patent</source><patent>EP2518070 A1</patent><year>2012</year><month>10</month><day>31</day></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="patent"><person-group person-group-type="inventor"><name><surname>Carrera Carrera</surname><given-names>F</given-names></name><name><surname>Perez Garcia</surname><given-names>J B</given-names></name><name><surname>Vidal Juan</surname><given-names>B</given-names></name><name><surname>Sanchez Izquierdo</surname><given-names>F</given-names></name><name><surname>Serra Coma</surname><given-names>M C</given-names></name></person-group><article-title>(S)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile</article-title><source>WO Patent</source><patent>WO2015181052 A1</patent><year>2015</year><month>12</month><day>3</day></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="patent"><person-group person-group-type="inventor"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name></person-group><article-title>Pyrrolo[2,1-f][1,2,4]triazine derivative, and preparation method and use thereof</article-title><source>WO Patent</source><patent>WO2015081783 A1</patent><year>2015</year><month>6</month><day>11</day></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="patent"><person-group person-group-type="inventor"><name><surname>Dzierba</surname><given-names>C D</given-names></name><name><surname>Dasgupta</surname><given-names>B</given-names></name><name><surname>Macor</surname><given-names>J E</given-names></name><name><surname>Bronson</surname><given-names>J J</given-names></name><name><surname>Rajamani</surname><given-names>R</given-names></name><name><surname>Karageorge</surname><given-names>G N</given-names></name></person-group><article-title>Pyrrolotriazine kinase inhibitors</article-title><source>WO Patent</source><patent>WO 2015054358 A1</patent><year>2015</year><month>4</month><day>16</day></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>M D</given-names></name><name><surname>Baker</surname><given-names>J</given-names></name><name><surname>Brubaker</surname><given-names>J D</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Kleinschek</surname><given-names>M A</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Maclean</surname><given-names>J K F</given-names></name><etal/></person-group><source>Bioorg Med Chem Lett</source><year>2015</year><volume>25</volume><fpage>5384</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.09.028</pub-id><pub-id pub-id-type="pmid">26403930</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesaros</surname><given-names>E F</given-names></name><name><surname>Angeles</surname><given-names>T S</given-names></name><name><surname>Albom</surname><given-names>M S</given-names></name><name><surname>Wagner</surname><given-names>J C</given-names></name><name><surname>Aimone</surname><given-names>L D</given-names></name><name><surname>Wan</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Olsen</surname><given-names>M</given-names></name><name><surname>Kordwitz</surname><given-names>E</given-names></name><etal/></person-group><source>Bioorg Med Chem Lett</source><year>2015</year><volume>25</volume><fpage>1047</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.01.019</pub-id><pub-id pub-id-type="pmid">25655723</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyndall</surname><given-names>E M</given-names></name><name><surname>Draffan</surname><given-names>A G</given-names></name><name><surname>Frey</surname><given-names>B</given-names></name><name><surname>Pool</surname><given-names>B</given-names></name><name><surname>Halim</surname><given-names>R</given-names></name><name><surname>Jahangiri</surname><given-names>S</given-names></name><name><surname>Bond</surname><given-names>S</given-names></name><name><surname>Wirth</surname><given-names>V</given-names></name><name><surname>Luttick</surname><given-names>A</given-names></name><name><surname>Tilmanis</surname><given-names>D</given-names></name><etal/></person-group><source>Bioorg Med Chem Lett</source><year>2015</year><volume>25</volume><fpage>869</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2014.12.069</pub-id><pub-id pub-id-type="pmid">25592710</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampognaro</surname><given-names>A J</given-names></name><name><surname>Wittman</surname><given-names>M D</given-names></name><name><surname>Carboni</surname><given-names>J M</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Greer</surname><given-names>A F</given-names></name><name><surname>Hurlburt</surname><given-names>W W</given-names></name><name><surname>Sack</surname><given-names>J S</given-names></name><name><surname>Vyas</surname><given-names>D M</given-names></name></person-group><source>Bioorg Med Chem Lett</source><year>2010</year><volume>20</volume><fpage>5027</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2010.07.045</pub-id><pub-id pub-id-type="pmid">20675137</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hynes</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Doubleday</surname><given-names>W W</given-names></name><name><surname>Dyckman</surname><given-names>A J</given-names></name><name><surname>Godfrey</surname><given-names>J D</given-names><suffix>Jr</suffix></name><name><surname>Grosso</surname><given-names>J A</given-names></name><name><surname>Kiau</surname><given-names>S</given-names></name><name><surname>Leftheris</surname><given-names>K</given-names></name></person-group><source>J Org Chem</source><year>2004</year><volume>69</volume><fpage>1368</fpage><pub-id pub-id-type="doi">10.1021/jo035587p</pub-id><pub-id pub-id-type="pmid">14961694</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazurkiewicz</surname><given-names>R</given-names></name></person-group><source>Monatsh Chem</source><year>1988</year><volume>119</volume><fpage>1279</fpage><pub-id pub-id-type="doi">10.1007/BF00808308</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazurkiewicz</surname><given-names>R</given-names></name></person-group><source>Monatsh Chem</source><year>1989</year><volume>120</volume><fpage>973</fpage><pub-id pub-id-type="doi">10.1007/BF00808768</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>D J</given-names></name><name><surname>Magomedov</surname><given-names>N A</given-names></name></person-group><source>J Am Chem Soc</source><year>2001</year><volume>123</volume><fpage>5892</fpage><pub-id pub-id-type="doi">10.1021/ja010066+</pub-id><pub-id pub-id-type="pmid">11414821</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhichkin</surname><given-names>P</given-names></name><name><surname>Kesicki</surname><given-names>E</given-names></name><name><surname>Treiberg</surname><given-names>J</given-names></name><name><surname>Bourdon</surname><given-names>L</given-names></name><name><surname>Ronsheim</surname><given-names>M</given-names></name><name><surname>Ooi</surname><given-names>H C</given-names></name><name><surname>White</surname><given-names>S</given-names></name><name><surname>Judkins</surname><given-names>A</given-names></name><name><surname>Fairfax</surname><given-names>D</given-names></name></person-group><source>Org Lett</source><year>2007</year><volume>9</volume><fpage>1415</fpage><pub-id pub-id-type="doi">10.1021/ol070276c</pub-id><pub-id pub-id-type="pmid">17348669</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>F</given-names></name><name><surname>Sinder</surname><given-names>B B</given-names></name></person-group><source>J Org Chem</source><year>1999</year><volume>64</volume><fpage>1397</fpage><pub-id pub-id-type="doi">10.1021/jo9820465</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ganesan</surname><given-names>A</given-names></name></person-group><source>J Org Chem</source><year>2000</year><volume>65</volume><fpage>1022</fpage><pub-id pub-id-type="doi">10.1021/jo9914364</pub-id><pub-id pub-id-type="pmid">10814050</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>A</given-names></name><name><surname>Tellitu</surname><given-names>I</given-names></name><name><surname>Dom&#x000ed;nguez</surname><given-names>E</given-names></name><name><surname>SanMartin</surname><given-names>R</given-names></name></person-group><source>J Org Chem</source><year>2006</year><volume>71</volume><fpage>3501</fpage><pub-id pub-id-type="doi">10.1021/jo060070+</pub-id><pub-id pub-id-type="pmid">16626131</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Dong</surname><given-names>D</given-names></name></person-group><source>J Org Chem</source><year>2011</year><volume>76</volume><fpage>2880</fpage><pub-id pub-id-type="doi">10.1021/jo101949y</pub-id><pub-id pub-id-type="pmid">21391701</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Sawant</surname><given-names>A A</given-names></name><name><surname>Chikhale</surname><given-names>R P</given-names></name><name><surname>Karanjai</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name></person-group><source>J Org Chem</source><year>2016</year><volume>81</volume><fpage>1645</fpage><pub-id pub-id-type="doi">10.1021/acs.joc.5b02796</pub-id><pub-id pub-id-type="pmid">26835801</pub-id></element-citation></ref></ref-list></back></article>